Anjo Sunny, M. Khan, Darpelly Mahesh, N. Chauhan, Ritu Mishra, Namindla Presila, A. Samuel
{"title":"RISK-BENEFIT ANALYSIS AND RISK MINIMIZATION OF QUINAPRIL: A REVIEW","authors":"Anjo Sunny, M. Khan, Darpelly Mahesh, N. Chauhan, Ritu Mishra, Namindla Presila, A. Samuel","doi":"10.3844/AJPTSP.2014.68.74","DOIUrl":null,"url":null,"abstract":"The purpose of this review is to give the readers a n insight about the risks and benefits of ‘quinapri l’, a potent Angiotensin Converting Enzyme Inhibitor (ACEI). Quinapril is a highly effective novel drug indicated for treatment of congestive heart failure and hypertension. Despite of the fact that safety profile is quite well with low incidence of adverse effects, a n attempt has been made to minimize the risks and subsequently minimizing the adverse consequences of this competitive inhibitor, thereby increasing the benefits of this enzyme inhibitor in day to day cli nical practice.","PeriodicalId":7769,"journal":{"name":"American Journal of Pharmacology and Toxicology","volume":"17 1","pages":"68-74"},"PeriodicalIF":0.0000,"publicationDate":"2014-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Pharmacology and Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3844/AJPTSP.2014.68.74","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The purpose of this review is to give the readers a n insight about the risks and benefits of ‘quinapri l’, a potent Angiotensin Converting Enzyme Inhibitor (ACEI). Quinapril is a highly effective novel drug indicated for treatment of congestive heart failure and hypertension. Despite of the fact that safety profile is quite well with low incidence of adverse effects, a n attempt has been made to minimize the risks and subsequently minimizing the adverse consequences of this competitive inhibitor, thereby increasing the benefits of this enzyme inhibitor in day to day cli nical practice.